Lu-177 PSMA Treatment in Cell Renal Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

February 1, 2028

Study Completion Date

August 1, 2028

Conditions
Metastatic Renal Cancer
Interventions
DRUG

Lu-177 PSMA-617

Included patients will receive 4 cycles of 7.4GBq Lu-177 PSMa therapy every 6 weeks. If any toxicity develops after the first cycle, dose reduction will be performed for the other cycles. At 1. And 4. Cycles of therapy, whole body planar and SPECT/CT imaging will be performed at 4. And 24. Hours and any time at 4-7.days of injection. On these images , kindey, liver and salivary gland doses will be calculated. Mean tumor dose will also be calculated by measurinf the tumoral uptake. In the follow up, patients will be controlled at 9. And 24. Weeks and every 12 months then after.

All Listed Sponsors
lead

Ankara University

OTHER